Trial · NCT07538258
Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
NCT07538258, Phase 2, Not yet recruiting, Yayi He
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer. Trials, record NCT07538258. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07538258
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Benmelstobart Plus Anlotinib, Chemotherapy and Thoracic Radiation for Limited-Stage Small Cell Lung Cancer
- NCT number
- NCT07538258
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 27 participants, estimated
- Lead sponsor
- Yayi He
- Conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Interventions
- Benmelstobart, Anlotinib, Cisplatin or carboplatin, Etoposide, Thoracic Radiation Therapy
- First posted
- 2026-04-20
- Last updated
- 2026-04-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Investigator-Assessed Objective Response Rate | Baseline at screening, after every 2 treatment cycles (each cycle is 21 days), end of treatment, up to disease progression, assessed up to approximately 24 months | According to RECIST 1.1 criteria, investigator assesses target lesion changes via imaging; calculates the proportion of subjects achieving complete response (CR) or partial response (PR) |
| Secondary | Serious Adverse Event (SAE) | from date of first study drug administration, follow-up until resolution or stabilization, assessed up to approximately 24 months | Collect SAEs resulting in death, life-threatening condition, hospitalization, disability per CTCAE 5.0 and ICH-GCP, document and report |
| Secondary | 6-Month Progression-Free Survival Rate | 6-month time point after first treatment, follow-up cutoff | Estimated proportion of subjects without progression and alive at 6 months after first treatment using Kaplan-Meier method |
| Secondary | Immune-Related Adverse Event (irAE) | From date of first study drug administration through 90 days after the last dose of study drug; assessed at baseline, each cycle visit, and unscheduled visits for suspected irAEs; graded per CTCAE 5.0 and irAE-specific criteria. | Identify and grade organ-specific immune-related adverse events according to CTCAE 5.0 and irAE criteria |
| Secondary | Progression-Free Survival (PFS) | From date of first study drug administration until the date of first documented disease progression (per RECIST v1.1) or death from any cause, whichever occurs first; assessed up to 24 months (maximum follow-up period). | Time from first treatment to disease progression or death from any cause, whichever occurs first |
| Secondary | 18-Month Overall Survival Rate | 18-month time point after first treatment, follow-up cutoff | Estimated proportion of alive subjects at 18 months after first treatment via Kaplan-Meier method |
| Secondary | 12-Month Overall Survival Rate | 12-month time point after first treatment, follow-up cutoff | Estimated proportion of alive subjects at 12 months after first treatment using Kaplan-Meier method |
| Secondary | 12-Month Progression-Free Survival Rate | 12-month time point after first treatment, follow-up cutoff | Estimated proportion of progression-free and alive subjects at 12 months via Kaplan-Meier method |
| Secondary | Overall Survival (OS) | From date of first study treatment to date of death from any cause or last follow-up, whichever occurs first, assessed up to approximately 24 months | Time from first study treatment to death from any cause; censored at last follow-up for alive subjects |
| Secondary | Disease Control Rate (DCR) | Time Frame: Baseline and after every 2 treatment cycles (each cycle is 21 days), up to disease progression, death, or study withdrawal, whichever occurs first，assessed up to approximately 24 months | According to RECIST 1.1, proportion of subjects achieving CR, PR, or stable disease (SD) in total enrolled population |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07538258
GET https://conductscience.org/api/trials/v1/NCT07538258/registered